Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Cortisone Shots Market Trends

ID: MRFR/Pharma/3419-HCR
110 Pages
Vikita Thakur
Last Updated: April 06, 2026

Cortisone Shots Market Research Report Information: By Type (Articular or Joint Injections, Epidural Steroid Injection, Trigger Point Injection), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Tendinitis, Allergic Reaction), End User - Global Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cortisone Shots Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Cortisone Shots Market

A key trend in the cortisone shots market is the increasing prevalence of musculoskeletal disorders, such as arthritis and tendinitis. As these conditions become more widespread, the demand for cortisone shots, known for their anti-inflammatory properties, is on the rise. This trend is shaping the market dynamics, with a focus on managing pain and inflammation associated with musculoskeletal issues. The market is experiencing an uptrend in the usage of cortisone shots, especially for sports injuries. These injections are also common among athletes and active people who suffer pain and inflammation due to conditions such as tennis elbow or sports-related joint injuries. This trend shows an increasing favour in cortisone shots that provide a rapid and efficient way of handling acute sports injuries. One prominent pattern is the persistent development of injection methods for cortisone shot administration. Healthcare professionals are using more focused and targeted methods with the help of imaging techniques like ultrasound or fluoroscopy. This trend is directed to increase the preciseness of injections which allow the cortisone to reach the affected area in the most favorable way and finally to improve the results of treatment. Cortisone shots market is branching out into dermatology. Cortisone injections are getting more popular among dermatologists for treatment of skin conditions which include keloids, cystic acne, and psoriasis. This also provides the market scope making dermatological applications a new opportunity and hence enlarging the overall market size. Patients seem to be opting for minimally invasive treatment types more and cortisone shots are one such treatment. Cortisone injections attract those who would rather avoid more invasive methods because they are non-surgical. This preference is determining market dynamics, pushing cortisone shots as a low-invasive intervention. A trend of moving towards individual treatment plans and personalized medicine is observed in the market. Cortisone shot regimens are customized by healthcare providers in relation to individual patient needs, factors such as the degree of the condition and patient preferences as well as potential side effects are taken into account. This development is a transition towards the patient-oriented care in cortisone shots market. Another common trend is the development of combination therapies concept of cortisone shots. The technology factor into pain management is affecting cortisone shots market. The digital health solutions, telemedicine and wearable devices are utilized to track the progress of the patients and provide remote consultations. This tendency improves the general patient satisfaction and contributes to quantitative and qualitative performance of cortisone shot services. Regulatory bodies are more and more focusing on the safety and efficacy of cortisone shots. Corticosteroid manufacturing, distribution, and administration are regulated by strict rules and guidelines. This pattern guarantees a concentration on patient safety and quality standards, which persuades the market-players to comply with rather stringent regulatory requirements.

The cortisone shots market is expanding in emerging economies where musculoskeletal disorders are on the rise. As healthcare infrastructure improves in these regions, there is a growing market potential for cortisone shots. Market players are strategically entering these markets, contributing to the global growth of the cortisone shots market.

Author
Author Profile
Vikita Thakur
Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Get In Touch

Leave a Comment

FAQs

What is the current market valuation of the Cortisone Shots Market?

The Cortisone Shots Market was valued at approximately 2142.97 USD Million in 2024.

What is the projected market valuation for the Cortisone Shots Market in 2035?

The market is projected to reach approximately 4710.17 USD Million by 2035.

What is the expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035?

The expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035 is 7.38%.

Which companies are considered key players in the Cortisone Shots Market?

Key players in the market include Pfizer, Merck & Co, Bristol-Myers Squibb, Sanofi, Amgen, AbbVie, Hikma Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries.

What are the primary applications of cortisone shots in the market?

The primary applications include Orthopedic, Dermatology, Rheumatology, Pulmonology, and Ophthalmology.

How does the market segment by administration route for cortisone shots?

The market segments by administration route include Intra-articular, Intramuscular, Intradermal, and Subcutaneous.

What demographic factors are considered in the Cortisone Shots Market?

Demographic factors include Age Group, Gender, Health Status, and Activity Level.

What are the different formulation types available in the Cortisone Shots Market?

Formulation types include Aqueous, Suspension, and Emulsion.

How is the treatment duration categorized in the Cortisone Shots Market?

Treatment duration is categorized into Short-term, Long-term, and Chronic.

What was the market valuation for the Orthopedic application segment in 2024?

The market valuation for the Orthopedic application segment was approximately 600.0 USD Million in 2024.

Market Summary

As per MRFR analysis, the Cortisone Shots Market Size was estimated at 2142.97 USD Million in 2024. The Cortisone Shots industry is projected to grow from 2325.68 in 2025 to 4710.17 by 2035, exhibiting a compound annual growth rate (CAGR) of 7.38% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Cortisone Shots Market is experiencing a notable shift towards non-surgical treatment options, driven by technological advancements and changing patient preferences.

  • The demand for non-surgical treatments is rising, particularly in North America, which remains the largest market for cortisone shots. Technological advancements in injection techniques are enhancing the efficacy and safety of cortisone administration, especially in the orthopedic segment. The Asia-Pacific region is emerging as the fastest-growing market, driven by increasing healthcare access and awareness of treatment options. Key market drivers include the increasing prevalence of chronic conditions and the growing geriatric population, which are fueling demand for effective non-invasive therapies.

Market Size & Forecast

2024 Market Size 2142.97 (USD Million)
2035 Market Size 4710.17 (USD Million)
CAGR (2025 - 2035) 7.38%
Largest Regional Market Share in 2024 North America

Major Players

Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL)

Market Trends

The Cortisone Shots Market is currently experiencing a notable evolution, driven by various factors that influence its dynamics. The increasing prevalence of inflammatory conditions, such as arthritis and tendinitis, has led to a heightened demand for cortisone injections as a therapeutic option. Additionally, advancements in medical technology and techniques have improved the efficacy and safety of these injections, making them a preferred choice among healthcare providers. As a result, patients are more likely to seek out cortisone shots for pain relief and inflammation management, contributing to the market's growth. Furthermore, the rising awareness of non-surgical treatment options is prompting both patients and practitioners to consider cortisone shots as a viable alternative to more invasive procedures. In parallel, the regulatory landscape surrounding cortisone shots is evolving, with an emphasis on ensuring patient safety and treatment effectiveness. Regulatory bodies are increasingly scrutinizing the manufacturing processes and clinical applications of these injections, which may lead to enhanced quality standards. This shift could potentially foster greater trust among consumers and healthcare professionals alike. Moreover, the expansion of telemedicine services is likely to influence the Cortisone Shots Market, as patients gain easier access to consultations and treatment options from the comfort of their homes. Overall, the market appears poised for continued growth, driven by a combination of medical advancements, regulatory changes, and shifting patient preferences.

Rising Demand for Non-Surgical Treatments

The Cortisone Shots Market is witnessing an increasing inclination towards non-surgical interventions. Patients are increasingly seeking alternatives to invasive procedures, leading to a surge in the popularity of cortisone injections for managing pain and inflammation. This trend reflects a broader shift in patient preferences, emphasizing the desire for less invasive treatment options.

Technological Advancements in Injection Techniques

Innovations in injection techniques and delivery systems are transforming the Cortisone Shots Market. Enhanced precision and safety in administering cortisone injections are likely to improve patient outcomes. These advancements may also contribute to a growing acceptance of cortisone shots among healthcare providers, further driving market growth.

Evolving Regulatory Frameworks

The regulatory environment surrounding cortisone shots is undergoing significant changes. Stricter guidelines and quality standards are being implemented to ensure patient safety and treatment efficacy. This evolution in regulations may enhance consumer confidence in cortisone injections, potentially leading to increased adoption in clinical practice.

Cortisone Shots Market Market Drivers

Aging Population

The aging population is a significant driver of the Global Cortisone Shots Market Industry. As individuals age, they are more likely to develop chronic conditions that require management through cortisone injections. The demographic shift towards an older population is evident in many countries, leading to an increased demand for effective pain relief solutions. This trend is particularly pronounced in developed nations, where healthcare systems are adapting to cater to the needs of older adults. Consequently, the market is poised for growth, with projections indicating a substantial increase in demand for cortisone shots in the coming years.

Market Growth Projections

The Global Cortisone Shots Market Industry is projected to experience substantial growth over the next decade. With a market value anticipated to reach 5.85 USD Billion by 2035, the industry is on a trajectory of expansion. This growth is underpinned by various factors, including the rising prevalence of chronic diseases, advancements in medical technology, and increasing patient awareness. The compound annual growth rate of 6.42% from 2025 to 2035 indicates a robust market environment, suggesting that cortisone shots will continue to play a vital role in pain management and treatment strategies globally.

Growing Awareness and Acceptance

There is a notable increase in awareness and acceptance of cortisone shots among patients and healthcare professionals, which is positively impacting the Global Cortisone Shots Market Industry. Educational initiatives and patient advocacy groups are playing a crucial role in informing individuals about the benefits and risks associated with cortisone injections. This growing understanding is leading to more patients seeking these treatments for pain management. As acceptance rises, the market is expected to grow, with estimates suggesting a market value of 5.85 USD Billion by 2035, indicating a robust future for cortisone shot therapies.

Regulatory Support and Guidelines

Regulatory support and updated clinical guidelines are fostering growth in the Global Cortisone Shots Market Industry. Health authorities are increasingly recognizing the therapeutic benefits of cortisone injections, leading to the establishment of clear guidelines for their use. This regulatory backing not only enhances the credibility of cortisone shots as a treatment option but also encourages healthcare providers to incorporate them into their practice. As a result, the market is likely to benefit from increased utilization and acceptance, further solidifying its position in the healthcare landscape.

Advancements in Medical Technology

Technological advancements in the administration of cortisone shots are significantly influencing the Global Cortisone Shots Market Industry. Innovations such as ultrasound-guided injections enhance precision and reduce complications, leading to improved patient outcomes. These advancements not only increase the efficacy of cortisone shots but also encourage healthcare providers to adopt these methods more widely. As a result, the market is likely to see a surge in demand, with a projected compound annual growth rate of 6.42% from 2025 to 2035. This growth reflects the ongoing evolution of treatment methodologies in the healthcare sector.

Rising Prevalence of Chronic Conditions

The Global Cortisone Shots Market Industry is experiencing growth due to the increasing prevalence of chronic conditions such as arthritis, asthma, and autoimmune disorders. As these conditions become more common, the demand for effective treatment options rises. Cortisone shots, known for their anti-inflammatory properties, are often utilized to manage pain and inflammation associated with these ailments. For instance, arthritis affects millions globally, leading to a heightened need for cortisone injections. This trend is expected to contribute to the market's expansion, with projections indicating a market value of 2.95 USD Billion in 2024.

Market Segment Insights

By Application: Orthopedic (Largest) vs. Dermatology (Fastest-Growing)

The Cortisone Shots Market showcases a varied distribution of market share across its application segments. Orthopedic applications hold the largest share as cortisone shots are primarily used for treating joint pain and inflammation, providing significant relief to patients with arthritis and similar conditions. Following closely, Dermatology is witnessing a rapid growth trend due to the increasing prevalence of skin disorders, including psoriasis and eczema, driving demand for cortisone injections. Growth in the Cortisone Shots Market is propelled by rising awareness of non-surgical pain management solutions across the healthcare landscape. The orthopedic segment benefits from a growing aging population actively seeking effective treatments for joint diseases, whereas dermatology is emerging as the fastest-growing application segment, fueled by advancements in drug formulations and a heightened focus on aesthetic treatments that require corticosteroid injections.

Orthopedic (Dominant) vs. Dermatology (Emerging)

Within the Cortisone Shots Market, the orthopedic segment stands out as the dominant application, primarily driven by its role in managing orthopedic conditions such as arthritis, tendonitis, and bursitis. This segment addresses the needs of a substantial patient population suffering from musculoskeletal disorders. In contrast, the dermatology segment is recognized as emerging, gaining traction due to increasing cases of skin conditions requiring intervention. The growth in dermatological applications is significantly impacted by the rise of chronic skin ailments and an increasing acceptance of cortisone shots as part of treatment regimens. This juxtaposition reveals a dynamic market where traditional therapies in orthopedics interface with the innovative behavioral shift towards dermatological treatments.

By Administration Route: Intra-articular (Largest) vs. Intramuscular (Fastest-Growing)

<p>In the Cortisone Shots Market, the 'By Administration Route' segment is prominently led by intra-articular injections, which capture the largest market share due to their targeted delivery to joints, ensuring effective pain relief for conditions like arthritis. Intramuscular administration follows, providing broader applicability across various medical scenarios, while intradermal and subcutaneous routes, though vital, hold smaller shares as they are less frequently used for cortisone delivery. The distribution reflects the preference of healthcare professionals and patients towards methods yielding faster and more efficient outcomes.</p>

<p>Administration Routes: Intra-articular (Dominant) vs. Intramuscular (Emerging)</p>

<p>Intra-articular administration is recognized as the dominant route for cortisone shots, particularly in treating joint pain and inflammation. Its targeted approach delivers medication directly into the affected area, leading to faster therapeutic effects and reduced systemic side effects, making it a preferred choice for many practitioners. On the other hand, the intramuscular route is emerging rapidly due to its versatility and ease of administration. It is gaining popularity among clinicians for its ability to deliver larger doses efficiently and its application in various inflammatory conditions. Both routes are crucial to the market, but intra-articular remains the go-to for joint-specific treatments.</p>

By Patient Demographics: Age Group (Largest) vs. Activity Level (Fastest-Growing)

<p>In the Cortisone Shots Market, patient demographics play a vital role in market share distribution. Age groups, particularly the older demographic, hold a significant share due to their higher prevalence of joint-related ailments. Following closely are younger adults who seek cortisone shots for sports injuries and chronic pain management. Gender distribution indicates that females are more likely to seek cortisone injections, primarily due to higher rates of autoimmune diseases. Meanwhile, activity level influences market share, where less active individuals tend to require cortisone treatments more frequently than those with a higher activity level.</p>

<p>Age Group (Dominant) vs. Activity Level (Emerging)</p>

<p>The aging population is the dominant force in the Cortisone Shots Market, largely because age correlates with increased susceptibility to conditions like arthritis and tendinitis. This demographic segment benefits from the prolonged medical use of cortisone shots as a treatment option for inflammation and pain. In contrast, the emerging activity level segment is rapidly gaining traction, particularly among younger adults engaged in sports. Increased participation in physical activities leads to a corresponding increase in injuries requiring cortisone treatments. As fitness trends continue to rise, this segment's importance is projected to grow, highlighting the need for targeted marketing strategies addressing the unique needs of active individuals.</p>

By Formulation Type: Aqueous (Largest) vs. Suspension (Fastest-Growing)

<p>In the Cortisone Shots Market, the formulation type segment is characterized by a diverse distribution among various options, including Aqueous, Suspension, and Emulsion. Aqueous formulations lead the market due to their established efficacy and ease of administration, capturing the largest share. Conversely, suspensions are rapidly gaining traction, particularly among physicians and patients who prefer their unique delivery capabilities. Emulsions, while present, hold a smaller share but play a relevant role for specific applications.</p>

<p>Aqueous (Dominant) vs. Suspension (Emerging)</p>

<p>Aqueous formulations dominate the Cortisone Shots Market, offering benefits such as quick absorption and minimal side effects, establishing their position as a preferred choice for practitioners. They are particularly advantageous in acute cases where immediate relief is necessary. In contrast, suspension formulations are emerging, characterized by their extended release profile, which appeals to patients requiring long-term management of inflammatory conditions. As awareness grows regarding the advantages of suspensions, innovations in formulation and delivery are expected to drive their broader adoption, positioning them as a significant alternative to traditional aqueous options.</p>

By Treatment Duration: Short-term (Largest) vs. Long-term (Fastest-Growing)

<p>The treatment duration segment in the cortisone shots market showcases a diverse distribution of market share among short-term, long-term, and chronic treatment options. Short-term cortisone shots have emerged as the dominant choice for patients experiencing acute conditions like arthritis or tendinitis, owing to their immediate relief capabilities. Long-term options, while initially trailing in prevalence, have gained traction as healthcare providers emphasize sustained relief in chronic pain management, leading to a notable shift in market preference over the recent years.</p>

<p>Long-term (Dominant) vs. Chronic (Emerging)</p>

<p>Long-term cortisone injections are increasingly recognized for their ability to provide consistent relief for chronic conditions such as autoimmune diseases and persistent joint pain, enabling patients to maintain a better quality of life. This segment is characterized by a growing acceptance within medical practices, driven by a strong emphasis on managing chronic conditions effectively. Conversely, chronic treatment options are emerging as a vital part of pain management strategies, appealing to a niche market that requires prolonged interventions. As patient awareness increases and treatment protocols evolve, the chronic segment is positioned to experience significant growth, catering to those seeking long-term solutions.</p>

Get more detailed insights about Cortisone Shots Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in Cortisone Shots

North America continues to lead the Cortisone Shots market, holding a significant share of approximately 1071.49 million in 2024. The growth is driven by increasing incidences of inflammatory conditions, advancements in healthcare infrastructure, and a robust regulatory framework that supports innovative therapies. The demand for effective pain management solutions is also on the rise, further propelling market expansion in this region. The competitive landscape is characterized by major players such as Pfizer, Merck & Co., and AbbVie, who are actively involved in research and development to enhance product offerings. The U.S. remains the largest market, benefiting from high healthcare expenditure and a well-established distribution network. The presence of leading pharmaceutical companies ensures a steady supply of Cortisone Shots, catering to the growing patient population.

Europe : Emerging Market with Growth Potential

Europe's Cortisone Shots market is valued at approximately 642.89 million, reflecting a growing demand driven by an aging population and increasing prevalence of chronic diseases. Regulatory bodies are actively promoting the use of corticosteroids for various inflammatory conditions, which is expected to further boost market growth. The region is witnessing a shift towards more personalized medicine, enhancing treatment efficacy and patient outcomes. Leading countries such as Germany, France, and the UK are at the forefront of this market, supported by strong healthcare systems and innovative research initiatives. Key players like Sanofi and Bristol-Myers Squibb are investing in new product developments and strategic partnerships to strengthen their market position. The competitive landscape is evolving, with a focus on improving patient access to Cortisone Shots across Europe.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing a burgeoning demand for Cortisone Shots, with a market size of approximately 357.89 million. Factors such as rising healthcare awareness, increasing disposable incomes, and a growing elderly population are driving this growth. Additionally, favorable government initiatives aimed at improving healthcare access are expected to further enhance market dynamics in the coming years. Countries like China and India are leading the market, supported by expanding healthcare infrastructure and a rising prevalence of chronic diseases. The competitive landscape includes key players such as Amgen and Hikma Pharmaceuticals, who are focusing on expanding their product portfolios and enhancing distribution channels. The region's market is characterized by a mix of local and international players, contributing to a dynamic competitive environment.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region represents a smaller segment of the Cortisone Shots market, valued at approximately 70.7 million. The growth in this region is hindered by limited healthcare infrastructure and varying regulatory environments. However, increasing awareness of chronic diseases and the need for effective treatment options are driving demand for Cortisone Shots. Government initiatives aimed at improving healthcare access are expected to support market growth in the future. Countries like South Africa and the UAE are leading the market, with a focus on enhancing healthcare services and increasing patient access to medications. The competitive landscape is evolving, with both local and international players striving to establish a foothold in this emerging market. Key players are exploring partnerships and collaborations to navigate the unique challenges of the region.

Key Players and Competitive Insights

The Cortisone Shots Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Pfizer (US), Merck & Co. (US), and AbbVie (US) are actively pursuing strategies that enhance their market positioning. Pfizer (US) has focused on expanding its product portfolio through research and development, particularly in the area of biologics, which may offer more targeted therapies. Merck & Co. (US) appears to be leveraging its extensive distribution network to optimize supply chains, ensuring that its cortisone products are readily available across various regions. AbbVie (US), on the other hand, has been investing in digital transformation initiatives to streamline operations and improve patient engagement, which collectively shapes a competitive environment that is dynamic and responsive to market needs.The business tactics employed by these companies include localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of products and services, catering to varying patient needs while fostering innovation through competition.
In November Merck & Co. (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to cortisone shot consultations. This move is significant as it aligns with the growing trend of digital health solutions, potentially increasing patient adherence to treatment protocols and improving overall outcomes. Such partnerships may also facilitate better data collection and analysis, which could inform future product development.
In October AbbVie (US) launched a new formulation of its cortisone injection, which reportedly offers a longer duration of action. This development is crucial as it addresses a common patient concern regarding the frequency of injections, thereby enhancing patient satisfaction and compliance. The introduction of this product may also position AbbVie favorably against competitors, as it demonstrates a commitment to innovation and responsiveness to patient needs.
In September Pfizer (US) expanded its manufacturing capabilities in Europe, aiming to increase production capacity for its cortisone products. This expansion is indicative of the company's strategy to meet rising global demand while ensuring supply chain reliability. By bolstering its manufacturing footprint, Pfizer may enhance its competitive edge, particularly in regions experiencing growth in cortisone shot utilization.
As of December current trends in the Cortisone Shots Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in operations. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

Key Companies in the Cortisone Shots Market include

Industry Developments

Future Outlook

Cortisone Shots Market Future Outlook

The Cortisone Shots Market is projected to grow at a 7.38% CAGR from 2025 to 2035, driven by increasing demand for pain management and advancements in injection techniques.

New opportunities lie in:

  • <p>Development of mobile app platforms for patient scheduling and education Expansion of <a href="https://www.marketresearchfuture.com/reports/telehealth-market-900">telehealth</a> services for remote cortisone shot consultations Partnerships with sports organizations for targeted pain management programs</p>

By 2035, the Cortisone Shots Market is expected to achieve robust growth and enhanced service delivery.

Market Segmentation

Cortisone Shots Market Application Outlook

  • Orthopedic
  • Dermatology
  • Rheumatology
  • Pulmonology
  • Ophthalmology

Cortisone Shots Market Formulation Type Outlook

  • Aqueous
  • Suspension
  • Emulsion
  • Powder

Cortisone Shots Market Distribution Channel Outlook

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Cortisone Shots Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Health Status
  • Activity Level

Cortisone Shots Market Route of Administration Outlook

  • Intra-articular
  • Intramuscular
  • Intradermal
  • Intraocular

Report Scope

MARKET SIZE 2024 2142.97(USD Million)
MARKET SIZE 2025 2325.68(USD Million)
MARKET SIZE 2035 4710.17(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.38% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL)
Segments Covered Application, Route of Administration, Formulation Type, Patient Demographics, Distribution Channel
Key Market Opportunities Growing demand for minimally invasive treatments drives innovation in the Cortisone Shots Market.
Key Market Dynamics Rising demand for cortisone shots drives innovation and competition among pharmaceutical manufacturers and healthcare providers.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current market valuation of the Cortisone Shots Market?

The Cortisone Shots Market was valued at approximately 2142.97 USD Million in 2024.

What is the projected market valuation for the Cortisone Shots Market in 2035?

The market is projected to reach approximately 4710.17 USD Million by 2035.

What is the expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035?

The expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035 is 7.38%.

Which companies are considered key players in the Cortisone Shots Market?

Key players in the market include Pfizer, Merck &amp; Co, Bristol-Myers Squibb, Sanofi, Amgen, AbbVie, Hikma Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries.

What are the primary applications of cortisone shots in the market?

The primary applications include Orthopedic, Dermatology, Rheumatology, Pulmonology, and Ophthalmology.

How does the market segment by administration route for cortisone shots?

The market segments by administration route include Intra-articular, Intramuscular, Intradermal, and Subcutaneous.

What demographic factors are considered in the Cortisone Shots Market?

Demographic factors include Age Group, Gender, Health Status, and Activity Level.

What are the different formulation types available in the Cortisone Shots Market?

Formulation types include Aqueous, Suspension, and Emulsion.

How is the treatment duration categorized in the Cortisone Shots Market?

Treatment duration is categorized into Short-term, Long-term, and Chronic.

What was the market valuation for the Orthopedic application segment in 2024?

The market valuation for the Orthopedic application segment was approximately 600.0 USD Million in 2024.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Million)
    2. | | 4.1.1 Orthopedic
    3. | | 4.1.2 Dermatology
    4. | | 4.1.3 Rheumatology
    5. | | 4.1.4 Pulmonology
    6. | | 4.1.5 Ophthalmology
    7. | 4.2 Healthcare, BY Administration Route (USD Million)
    8. | | 4.2.1 Intra-articular
    9. | | 4.2.2 Intramuscular
    10. | | 4.2.3 Intradermal
    11. | | 4.2.4 Subcutaneous
    12. | 4.3 Healthcare, BY Patient Demographics (USD Million)
    13. | | 4.3.1 Age Group
    14. | | 4.3.2 Gender
    15. | | 4.3.3 Health Status
    16. | | 4.3.4 Activity Level
    17. | 4.4 Healthcare, BY Formulation Type (USD Million)
    18. | | 4.4.1 Aqueous
    19. | | 4.4.2 Suspension
    20. | | 4.4.3 Emulsion
    21. | 4.5 Healthcare, BY Treatment Duration (USD Million)
    22. | | 4.5.1 Short-term
    23. | | 4.5.2 Long-term
    24. | | 4.5.3 Chronic
    25. | 4.6 Healthcare, BY Region (USD Million)
    26. | | 4.6.1 North America
    27. | | | 4.6.1.1 US
    28. | | | 4.6.1.2 Canada
    29. | | 4.6.2 Europe
    30. | | | 4.6.2.1 Germany
    31. | | | 4.6.2.2 UK
    32. | | | 4.6.2.3 France
    33. | | | 4.6.2.4 Russia
    34. | | | 4.6.2.5 Italy
    35. | | | 4.6.2.6 Spain
    36. | | | 4.6.2.7 Rest of Europe
    37. | | 4.6.3 APAC
    38. | | | 4.6.3.1 China
    39. | | | 4.6.3.2 India
    40. | | | 4.6.3.3 Japan
    41. | | | 4.6.3.4 South Korea
    42. | | | 4.6.3.5 Malaysia
    43. | | | 4.6.3.6 Thailand
    44. | | | 4.6.3.7 Indonesia
    45. | | | 4.6.3.8 Rest of APAC
    46. | | 4.6.4 South America
    47. | | | 4.6.4.1 Brazil
    48. | | | 4.6.4.2 Mexico
    49. | | | 4.6.4.3 Argentina
    50. | | | 4.6.4.4 Rest of South America
    51. | | 4.6.5 MEA
    52. | | | 4.6.5.1 GCC Countries
    53. | | | 4.6.5.2 South Africa
    54. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Pfizer (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Merck & Co (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Bristol-Myers Squibb (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Sanofi (FR)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Amgen (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 AbbVie (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Hikma Pharmaceuticals (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Mylan (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Teva Pharmaceutical Industries (IL)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY APPLICATION
    4. | 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. | 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. | 6.6 US MARKET ANALYSIS BY FORMULATION TYPE
    7. | 6.7 US MARKET ANALYSIS BY TREATMENT DURATION
    8. | 6.8 CANADA MARKET ANALYSIS BY APPLICATION
    9. | 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    10. | 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    11. | 6.11 CANADA MARKET ANALYSIS BY FORMULATION TYPE
    12. | 6.12 CANADA MARKET ANALYSIS BY TREATMENT DURATION
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    16. | 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    17. | 6.17 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
    18. | 6.18 GERMANY MARKET ANALYSIS BY TREATMENT DURATION
    19. | 6.19 UK MARKET ANALYSIS BY APPLICATION
    20. | 6.20 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
    21. | 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    22. | 6.22 UK MARKET ANALYSIS BY FORMULATION TYPE
    23. | 6.23 UK MARKET ANALYSIS BY TREATMENT DURATION
    24. | 6.24 FRANCE MARKET ANALYSIS BY APPLICATION
    25. | 6.25 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    26. | 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    27. | 6.27 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
    28. | 6.28 FRANCE MARKET ANALYSIS BY TREATMENT DURATION
    29. | 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
    30. | 6.30 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    31. | 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    32. | 6.32 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
    33. | 6.33 RUSSIA MARKET ANALYSIS BY TREATMENT DURATION
    34. | 6.34 ITALY MARKET ANALYSIS BY APPLICATION
    35. | 6.35 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    36. | 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    37. | 6.37 ITALY MARKET ANALYSIS BY FORMULATION TYPE
    38. | 6.38 ITALY MARKET ANALYSIS BY TREATMENT DURATION
    39. | 6.39 SPAIN MARKET ANALYSIS BY APPLICATION
    40. | 6.40 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    41. | 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    42. | 6.42 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
    43. | 6.43 SPAIN MARKET ANALYSIS BY TREATMENT DURATION
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY TREATMENT DURATION
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY APPLICATION
    51. | 6.51 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    52. | 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    53. | 6.53 CHINA MARKET ANALYSIS BY FORMULATION TYPE
    54. | 6.54 CHINA MARKET ANALYSIS BY TREATMENT DURATION
    55. | 6.55 INDIA MARKET ANALYSIS BY APPLICATION
    56. | 6.56 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    57. | 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    58. | 6.58 INDIA MARKET ANALYSIS BY FORMULATION TYPE
    59. | 6.59 INDIA MARKET ANALYSIS BY TREATMENT DURATION
    60. | 6.60 JAPAN MARKET ANALYSIS BY APPLICATION
    61. | 6.61 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    62. | 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    63. | 6.63 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
    64. | 6.64 JAPAN MARKET ANALYSIS BY TREATMENT DURATION
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY TREATMENT DURATION
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY TREATMENT DURATION
    75. | 6.75 THAILAND MARKET ANALYSIS BY APPLICATION
    76. | 6.76 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
    77. | 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    78. | 6.78 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
    79. | 6.79 THAILAND MARKET ANALYSIS BY TREATMENT DURATION
    80. | 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
    81. | 6.81 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    82. | 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    83. | 6.83 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
    84. | 6.84 INDONESIA MARKET ANALYSIS BY TREATMENT DURATION
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY TREATMENT DURATION
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
    92. | 6.92 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
    93. | 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    94. | 6.94 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
    95. | 6.95 BRAZIL MARKET ANALYSIS BY TREATMENT DURATION
    96. | 6.96 MEXICO MARKET ANALYSIS BY APPLICATION
    97. | 6.97 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
    98. | 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    99. | 6.99 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
    100. | 6.100 MEXICO MARKET ANALYSIS BY TREATMENT DURATION
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY TREATMENT DURATION
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT DURATION
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT DURATION
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT DURATION
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY TREATMENT DURATION
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    135. | 6.135 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    137. | 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    139. | 6.139 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
    141. | 6.141 HEALTHCARE, BY TREATMENT DURATION, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY TREATMENT DURATION, 2024 TO 2035 (USD Million)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
    5. | | 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    6. | | 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    7. | | 7.2.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    8. | | 7.2.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
    11. | | 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    12. | | 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    13. | | 7.3.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    14. | | 7.3.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
    17. | | 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    18. | | 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    19. | | 7.4.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    20. | | 7.4.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
    23. | | 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    24. | | 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    25. | | 7.5.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    26. | | 7.5.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
    29. | | 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    30. | | 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    31. | | 7.6.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    32. | | 7.6.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
    35. | | 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    36. | | 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    37. | | 7.7.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    38. | | 7.7.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
    41. | | 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    42. | | 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    43. | | 7.8.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    44. | | 7.8.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
    47. | | 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    48. | | 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    49. | | 7.9.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    50. | | 7.9.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
    53. | | 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    54. | | 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    55. | | 7.10.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    56. | | 7.10.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
    59. | | 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    60. | | 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    61. | | 7.11.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    62. | | 7.11.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
    65. | | 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    66. | | 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    67. | | 7.12.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    68. | | 7.12.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
    71. | | 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    72. | | 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    73. | | 7.13.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    74. | | 7.13.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
    77. | | 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    78. | | 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    79. | | 7.14.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    80. | | 7.14.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
    83. | | 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    84. | | 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    85. | | 7.15.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    86. | | 7.15.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
    89. | | 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    90. | | 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    91. | | 7.16.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    92. | | 7.16.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
    95. | | 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    96. | | 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    97. | | 7.17.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    98. | | 7.17.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
    101. | | 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    102. | | 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    103. | | 7.18.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    104. | | 7.18.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
    107. | | 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    108. | | 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    109. | | 7.19.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    110. | | 7.19.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
    113. | | 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    114. | | 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    115. | | 7.20.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    116. | | 7.20.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
    119. | | 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    120. | | 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    121. | | 7.21.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    122. | | 7.21.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
    125. | | 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    126. | | 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    127. | | 7.22.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    128. | | 7.22.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
    131. | | 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    132. | | 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    133. | | 7.23.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    134. | | 7.23.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
    137. | | 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    138. | | 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    139. | | 7.24.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    140. | | 7.24.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
    143. | | 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    144. | | 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    145. | | 7.25.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    146. | | 7.25.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
    149. | | 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    150. | | 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    151. | | 7.26.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    152. | | 7.26.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
    155. | | 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    156. | | 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    157. | | 7.27.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    158. | | 7.27.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
    161. | | 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    162. | | 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    163. | | 7.28.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    164. | | 7.28.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
    167. | | 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    168. | | 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    169. | | 7.29.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    170. | | 7.29.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
    173. | | 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
    174. | | 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
    175. | | 7.30.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
    176. | | 7.30.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Orthopedic
  • Dermatology
  • Rheumatology
  • Pulmonology
  • Ophthalmology

Healthcare By Administration Route (USD Million, 2025-2035)

  • Intra-articular
  • Intramuscular
  • Intradermal
  • Subcutaneous

Healthcare By Patient Demographics (USD Million, 2025-2035)

  • Age Group
  • Gender
  • Health Status
  • Activity Level

Healthcare By Formulation Type (USD Million, 2025-2035)

  • Aqueous
  • Suspension
  • Emulsion

Healthcare By Treatment Duration (USD Million, 2025-2035)

  • Short-term
  • Long-term
  • Chronic
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓